POSTER SESSIONS

Sunday 7th December
3.30 – 4.00pm and 5.30 – 6.30pm

Human Vaccines Infectious Disease
Abstract numbers P1 – P77

Human Vaccines Non Infectious Disease
Abstract number P78

Monday 8th December
10.30 – 11.00am, 12.30 – 1.30 and 4.00 – 4.30pm

Late Breaker
Abstract numbers P97 – P144

Other
Abstract numbers P145 – P150

Production
Abstract numbers P151 – 154

Vectors, Adjuvants, Delivery Systems
Abstract numbers P155 - P174

Tuesday 9th December
10.30 – 11.00am and 12.45 – 1.15pm

Veterinary Vaccines
Abstract numbers P175 – P192

Immunology/Animal Models
Abstract numbers P79 - P96

POSTER PRESENTATION INDEX

P1 Immunogenicity of Pneumococcal Vaccine Among elderly hospitalised patients
I Ridda[1], CR MacIntyre[1,5], PB McIntyre[1], *[1]National Centre for Immunization Research and Surveillance, Australia, [2]Discipline of Medicine: Geriatric Medicine. The University of Sydney, Australia, [3]The Australian Red Cross blood services, Australia, [4]School of Public Health and Community Medicine. The University of New South Wales, Australia, [5]School of Public Health and Community Medicine. The University of New South Wales, Australia*

P2 Vaccinal Prevention of Hepatitis B: Do "Poor" Children Benefit it as Much as "Rich" Children?
Vien NGUYEN CONG[1,2], Thien CHAU PHAT[1], *[1]Children's Hospital N2, Viet Nam, [2]GSK Biologicals, Viet Nam*

P3 Protective Cellular and Humoral Immune Responses Induced by Mucosal Vaccines Against Streptococcus pneumoniae
D. M. Ferreira[1], M. Darrieux[1], L. C. C. Leite[1], P. L. Ho[1], E. N. Miyaji[1], M. L. S. Oliveira[1], *[1]Instituto Butantan, Brazil*

P4 Flavitrack, a database to determine functional and immunologically important regions of Flavivirus sequences.
Petr Danecek[1], Catherine H. Schein[1], *[1]University of Texas Medical Branch, United States*

P5 Immunogenetic correlates of immune response to the smallpox vaccine
I.G. Ovsyannikova[1], R.M. Jacobson[1], R.A. Vierkant[1], V.S. Pankratz[1], G.A. Poland[1], *[1]Mayo Clinic College of Medicine, United States*

P6 Cluster of Invasive Streptococcus pneumoniae Among Adults: Reminder To Vaccinate
RJ Nett[1,2], KK Carter[1,2], *[1]Centers for Disease Control and Prevention, United States, [2]Idaho Department of Health and Welfare, United States*

P7 Active Epidemiologic Surveillance of Invasive Pneumococcal Disease (IPD) and Chest Radiograph (CXR)-Confirmed Pneumonia (CXR+Pn) in Children in San José, Costa Rica
A. Arguedas[1], A. Abdelnour[1], R. Dagan[2], S. Gray[3], J. Markowitz[3], G.L. Rodgers[3], *[1]Instituto de Atención Pediátrica,Universidad de Ciencias Médicas, Caja Costarricense de Seguro Social, Costa Rica, [2]Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel, [3]Wyeth Pharmaceuticals, United States*

P8 Intradermal Hepatitis B Vaccination in Non-responders after Topical Application of Imiquimod (Aldara□) on the Vaccinated Skin
AHE Roukens[1], GJ Boland[2], ACTM Vossen[1], JT van Dissel[1], LG Visser[1], *[1]Leiden University Medical Center, Netherlands, [2]University Medical Center Utrecht, Netherlands*

P9 Influenza A Virus Matrix Protein 1-Specific Human CD8+ T Cell Response Induced in Trivalent Inactivated Vaccine Recipients
M Terajima[1], J Cruz[1], AM Leporati[1], L Orphin[1], JAB Babon[1], MDT Co[1], *[1]University of Massachusetts Medical School, United States*

P10 SARS-CoV S Protein Induces Strong Mucosal Immune Responses and Provides Long-term Protection Against SARS-CoV Infection
BJ Zheng[1], L Du[1,2], G Zhao[1], *[1]Department of Microbiology, The University of Hong Kong, China, [2]Lindsley F. Kimball Research Institute, The New York Blood Center,, United States, [3]Department of Immunology, Zhongshan School of Medicine, Sun Yat-sen University, China, [4]Department of Biochemistry, The University of Hong Kong, China, [5]State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, China*

P11 Epidemiologic Surveillance of Invasive Pneumococcal Disease (IPD) and Chest Radiograph (CXR)-Confirmed Pneumonia (CXR+Pn) in Children in Bogota, Colombia
J.A. Benavides[1], C. Reyes[2], M. Flitter[3], J. Markowitz[3], G.L. Rodgers[3], *[1]Centro Nacional de Investigación, Grupo SaludCoop, Colombia, Colombia, [2]Wyeth Pharmaceuticals, Colombia, Colombia, [3]Wyeth Pharmaceuticals, USA, United States*

P12 Pertussis in Adults with Persistent Cough: A Prospective Follow Up Study in Primary Care, Spain
J Puig-Barbera[1], J Diez-Domingo[2], E Pastor-Villalba[4], J García-Lomas[3], I Huertas-Zarco[4], S Pérez-Hoyos[5], *[1]Centre Salut Pública Castello, Spain, [2]Valencia Vaccine Institute, Spain, [3]Instituto Valenciano de Microbiología, Spain, [4]Dirección General de Salud Pública, Spain, [5]Escuela Valenciana Estudio de Salud, Spain*

P13 An improved protocol for the synthesis of Haemophilus influenzae type b capsular polysaccharide and tetanus toxoid conjugated antigen .
APAL Lorthiois[1], MT Takagi[1], JCC Cabrera-Crespo[1], IR Raw[1], MMT Tanizaki[1], *[1]Instituto Butantan, Brazil*

P14 Development of a candidate vaccine to HCV using a plant virus based adjuvant.
Christian Savard[1], Denis Leclerc[1], *[1]Infectious disease research center, Canada*

P15 Development of a vaccine against chlamydial STD infection and disease
P Timms[1], K Beagley[1], L Hafner[1], *[1]Queensland University of Technology, Australia*

P16 Scheduling of Measles Vaccination Campaigns in Low-income Countries: Projections of a Dynamic Model
CT Bauch[2], E Szusz[2], BW Bresnahan[1], T Hazlet[1], S Kadiyala[1], D Veenstra[1], L Garrison[1], *[1]Department of Pharmacy, University of Washington, United States, [2]Department of Mathematics and Statistics, University of Guelph, Canada*

P17 Cost-effectiveness of adding new rotavirus vaccines to the national immunization program in Kyrgyzstan
E.T. Flem[1], R. Latipov[2,3], Z.S. Nurmativ[4], Y. Xue[3], K.T. Kasymbekova[4], R. Rheingans[5], *[1]Norwegian Institute of Public Health, Norway, [2]Research Institute of Virology, Uzbekistan, [3]University of Oslo, Norway, [4]Department of State Sanitary-Epidemiologic Surveillance, Ministry of Health, Kyrgyzstan, [5]Rollins School of Public Health, Emory University, United States*

P18 Burden of Pneumococcal Disease (PD) in Eastern Europe: Importance of Inclusion of Pneumococcal Conjugate Vaccine (PCV) into National Immunization Programs (NIPs)
C. Burman[1], K.J. Center[1], D.J. Isaacman[1], *[1]Wyeth Pharmaceuticals, United States*

P19 Burden of Pneumococcal Disease (PD) in Latin America (LA): Importance of Inclusion of Pneumococcal Conjugate Vaccine (PCV) into National Immunization Programs (NIPs)
C.S. Garcia[1], K.J. Center[1], G.L. Rodgers[1], R.R. Reinert[2], R. Dagan[3], A. Arguedas[4], *[1]Wyeth Pharmaceuticals, United States, [2]Wyeth Research, France, [3]Pediatric Infectious Disease Unit, Soroka University Medical Center and the Faculty of Health Sciences, Ben-Gurion University of the Negev, Israel, [4]Instituto de Atención Pediátrica, Universidad de Ciencias Médicas, Costa Rica*

P20 Burden of Pneumococcal Disease (PD) in the Asia-Pacific (AP) Region: Importance of Inclusion of Pneumococcal Conjugate Vaccine (PCV) into National Immunization Programs (NIPs)
C.S. Garcia[1], K.J. Center[1], G. Herrera[1], *[1]Wyeth Pharmaceuticals, United States*

P21 Comparison of ELISA and toxin neutralization to detect changes in immunogenicity of anthrax vaccines in mice
J.A. Castelan-Vega[1], L. Sirota[2], P. Parreiras[2], J.L. Arciniega[2], *[1]Escuela Nacional de Ciencias Biologicas, Mexico, [2]Center for Biologics Evaluation and Research, United States*

P22 B- and T-Cell-Mediated Protection Induced by Nasal Administration Using Live Attenuated Bordetella pertussis BPZE1

Pascal Feunou Feunou[1], Anne-Sophie Debrie[1], Julie Bertout[1], Camille Locht[1], [1]*Institut Pasteur de Lille, France*

P23 Hospitalisation of children with varicellae in an unvaccinated population during 1998-2007

A Nilsson[1], M Eriksson[1], P Grimheden[1], R Bennett[1], Anders Hjern[2], [1]*Karolinska Institutet, Sweden,* [2]*National Board of Health and Welfare, Sweden*

P24 Heterologous HA DNA vaccine prime - inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses

S. Wang[1], C. Parker[1], J. Taaffe[2], A. Solórzano[2], A. García-Sastre[2], S. Lu[1], [1]*University of Massachusetts Medical School, United States,* [2]*Mount Sinai School of Medicine, United States*

P25 In Vitro Evidence that Commercial Influenza Vaccines Are Not Similar in Their Ability to Activate Human T Cell Responses

M Co[1], L Orphin[1], J Cruz[1], P Pazoles[1], F Ennis[1], M Terajima[1], [1]*University of Massachusetts Medical School, United States*

P26 ELVIRA A and ELVIRA B: Two Genetically Engineered Human Cell Lines Expressing Influenza Inducible Reporters for Detecting and Quantifying Influenza Virus A and B

Y LI[1], T Curtiss[1], D Scholl[1], P Olivo[1], A Pekosz[2], A Larrimer[1], [1]*Diagnostic Hybrids, United States,* [2]*Johns Hopkins Bloomberg School of Public Health, United States*

P27 Selection of HIV-1 subtype A phage libraries for HIV preventive vaccine development

A.N. Galkin[1], A.I. Soloviev[1], S.M. Kiselev[1], E.Y. Gagarina[1], A.B. Bychenko[1], E.Y. Filinova[1], [1]*Advanced Biomedical Researches Laboratory, Russian Federation*

P28 Serotyping S. pneumoniae by Bio-Plex Multiplex antigen detection assay and protective spectrum of 3 different conjugated pneumococcal vaccine

M Ceyhan[1], RC George[2], C Sheppard[2], I Yildirim[1], [1]*Hacettepe University, School of Medicine, Department of Pediatric Infectious Diseases, Turkey,* [2]*Respiratory & Systemic Infection Laboratory, United Kingdom*

P29 Postpartum Immunization Against Pertussis in a High-Risk Population

C.M. Healy[1,2], M.A. Rench[1,2], C.A. Cullinan[1], L. Castagnini[2], C.J. Baker[1,2], [1]*Center for Vaccine Awareness and Research, Texas Children's Hospital, United States,* [2]*Baylor College of Medicine, United States*

P30 Clinical impact of cholera toxin B subunit expressed rice-based vaccine(MucoRice): Crucial protective role of antigen specific secretory IgA and cross-protection against cholera toxin and E.coli heat labile enterotoxin

D Tokuhara[1], Y Yuki[1], T Nochi[1], M Mejima[1], S Kurokawa[1], H Kiyono[1], [1]*The Institute of Medical Science, The University of Tokyo, Japan*

P31 A 5- year follow- up of antibody response in children vaccinated with single dose of live attenuated SA-14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses

Jay Bahadur Tandan[1], Young Mo Sohn[1], Sutee Yoksan[1], Min Ji[1], Heechoul Ohrr[1], [1]*Japanese Encephalitis Support Group, Nepal,* [2]*Younsei University, College of Medicine, Department of Paediatrics, Korea, Republic of,* [3]*Mahidol University, Vaccine Development Center, Thailand,* [4]*Yonsei University, College of Medicine, Department of Preventive Medicine, Korea, Republic of,* [5]*Yonsei University, College of Medicine, Department of Preventive Medicine, Korea, Republic of*

P32 Inactivated recombinant HCV particle immunization of mice could induce antibody response,

Omi Noriaki[1,2], Akazawa Daisuke[1,2], Takahashi Hitoshi[1,2], Ishii Koji[2], Suzuki Tetsuro[2], Wakita Takaji[2], [1]*Toray Industry, Inc., Japan,* [2]*National Institute of Infectious Diseases, Japan*

P33 Development of a Peptide Based Universal Influenza Vaccine
PL Smith[1], K Norgate[1], E Hegarty[1], [1]*St George's University of London, United Kingdom*

P34 Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine Given with Routine Pediatric Vaccination to Healthy Infants in France
E. Grimprel[1], D. Scott[2], F. Laudat[3], S. Baker[2], W. Gruber[2], PCV13 Multicenter Study Group[4], [1]*Hôpital Armand Trousseau, France,* [2]*Wyeth Vaccine Research, United States,* [3]*Wyeth Vaccine Research, France,* [4]*Multiple investigational sites, France*

P35 Estimated Cost–Effectiveness of Heptavalent Pneumococcal Conjugated Vaccine (PCV7) in Colombian Children
M Santa Maria[1], F Garcia[1], MJ Uribe[1], [1]*Economic Studies Center, FEDESARROLLO, Colombia*

P36 An update of the GARDASIL□ (Quadrivalent Human Papillomavirus [HPV] Vaccine) Clinical Trial Program
R.M. Haupt[1], [1]*Merck Research Laboratories, United States*

P37 A Universal Influenza Vaccine Using an M2e/NP Fusion Protein Linked to Immunostimulatory Sequences (ISS)
D Higgins[1], T dela Cruz[1], R Milley[1], A Hillebrand[2], C Amuel[2], G Van Nest[1], [1]*Dynavax Technologies, United States,* [2]*Dynavax - Europe, Germany,* [3]*Baylor College of Medicine, United States*

P38 A Novel Plasmid DNA Technology (GTU) Applied As A Potential HIV1/AIDS Therapeutic Vaccine
EV Vardas[1], C Gray[2], I Stanescu[3], V Blazevic[3], M Valtavaara[3], M Leinonen[4], [1]*University of Witwatersrand, Perinatal HIV Research Unit, Soweto,, South Africa,* [2]*National Institute of Communicable Diseases, South Africa,* [3]*FIT Biotech Plc, Finland,* [4]*4 Pharma, Finland,* [5]*FIT Biotech Plc, Estonia,* [6]*Institute of Technology, Estonia*

P39 A Randomized, Double Blind, Controlled Clinical Trial to Evaluate the Efficacy and Safety of CJ-50300, a Newly Developed Cell-Culture Derived Smallpox Vaccine in Healthy Volunteers
HC Jang[1], S Lee[1], KH Song[1], WB Park[1], M Oh[1], KW Choe[1], [1]*Seoul National University, Korea, Republic of*

P40 Persistence of influenza vaccine seroprotection in lung transplant patients
MS Hayney[1], JJM Moran[1], [1]*University of Wisconsin School of Pharmacy, United States*

P41 Modelling the benefits of vaccinating the elderly in Ontario with an intradermal influenza vaccine
S Aballéa[1], J Roïz[1], J Kwong[2], C Reygrobellet[3], [1]*i3 Innovus, United Kingdom,* [2]*Institute for Clinical Evaluative Sciences, Canada,* [3]*Sanofi Pasteur, France*

P42 Alphavirus Vector-based Vaccine Development Against Argentine Hemorrhagic Fever
A.V. Seregin[1], N.E. Yun[1], S. Paessler[1], [1]*University of Texas Medical Branch, United States*

P43 Impact of Missed PCV7 Doses on Burden of Lower Respiratory Tract Disease in Children
S.I. Pelton[1], D. Weycker[2], J.O. Klein[1], D. Strutton[3], V. Ciuryla[3], G. Oster[2], [1]*Boston University Schools of Medicine and Public Health, United States,* [2]*Policy Analysis Inc. (PAI), United States,* [3]*Wyeth Research, United States*

P44 Public Health and Economic Impact of 7-valent Pneumococcal Conjugate Vaccination in an Influenza Pandemic in the US
J.L. Rubin[1], L.J. McGarry[1], K. Klugman[2], D. Strutton[3], V. Ciuryla[3], K. Gilmore[1], [1]*i3 Innovus, United States,* [2]*Emory University, United States,* [3]*Wyeth Research, United States*

P45 Obstacles in the motivation of health care workers for pertussis vaccination
S Wicker[1], S Zielen[2], MA Rose[2], [1]*University Hospital, Occupational Health Service, Germany,* [2]*University Hospital, Children´s Hospital, Germany*

P46 The Effect Of High-Dose Vitamin A Supplementation Administered With BCG Vaccine At Birth May Be Modified By Subsequent DTP Vaccination

CS Benn[1], A Rodrigues[2], M Yazdanbakhsh[3], *[1]Bandim Health Project, Statens Serum Institut, Denmark, [2]Bandim Health Project, Indepth Network, Guinea-Bissau, [3]Department of Immunoparasitology, Leiden University Medical Centre, Netherlands, [4]The MRC Laboratories, Gambia*

P47 Safety and immunogenicity of an influenza vaccine A/H5N1 administered with and without a heat-labile enterotoxin (LT) patch in healthy adults

G M Glenn[1], S A Frech[1], J Wen[1], D N Thomas[1], *[1]Iomai Corporation, United States*

P48 Diphtheria-Tetanus-Pertussis Vaccine and Child Survival in Low-Income Countries: Non-Specific and Sex-Differential Effects

P Aaby[1], CS Benn[1], *[1]Bandim Health Project, Guinea-Bissau*

P49 Medical Grade Extracellular Matrix As A Novel Vaccine Adjuvant

P Hall[1], M Hiles[1], M Suckow[2], *[1]Cook Biotech Inc, United States, [2]University of Notre Dame, United States*

P50 Desired Immune Response Characteristics In An RSV Vaccine: What Infants Tell Us

JL Reed[1], L Avendano[2], L Velozo[3], RC Welliver, Sr[4], *[1]Food and Drug Administration, Center for Biologics Evaluation and Research, United States, [2]Programa de Virología, Universidad de Chile, Chile, [3]Unidad de Anatomía Patológica, Hospital Roberto del Río, Chile, [4]Women and Children's Hospital, United States*

P51 Effective increasing the immunogenicity of a marketed Pneumococcal vaccine by addition of a nanoparticulate adjuvant, Posintro™, formulated with a protein antigen.

A Schiott[1], S Manniche[1], N Kirkby[1], *[1]KMA-Rigshospital, Denmark*

P52 The Immunogenicity and Efficacy of a Virus-like Particle Vaccine Candidate against Respiratory Syncytial Virus in Mice

L McGinnes[1], M Murawski[1], R Finberg[1], E Kurt-Jones[1], A Frair[1], K Mahmood[2], Y Wu[2], P Pushko[2], P Heaton[2], T Morrison[1], *[1]University of Massachusetts, United States, [2]Novavax, United States*

P53 Role of CD4+ and CD8+ T Cells in Protection against Lethal Encephalitis Mediated by a Sinbis-VEEV Chimeric Vaccine

N.E. Yun[1], A.S. Bertke[1], M.A. Zacks[1], A.L. Poussard[1], J.K. Smith[1], S. Paessler[1], *[1]University of Texas Medical Branch, United States*

P54 Active Epidemiologic Surveillance of Invasive Pneumococcal Disease (IPD) and Chest Radiograph (CXR) Confirmed Pneumonia (CXR+Pn) in Children in Goiânia, Brazill

A.L.S.S. Andrade[1], R. Oliveira[1], M.A. Vieira[1], R. Minamisava[2], V. Pessoa, Junior[1], M.C.C. Brandileone[3], *[1]Institute of Tropical Pathology and Public Health, Federal University of Goiás, Brazil, [2]School of Nursing, Federal University of Goiás, Brazil, [3]Adolfo Lutz Institute, Brazil, [4]Wyeth Pharmacetuticals, Brazil, [5]Wyeth Pharmaceuticals, United States*

P55 Identifying Potential Vaccination Innovations for Measles in Developing Countries: Horizon Scanning and Technical Assessment

T Hazlet[1], P Gillard[1], C Bauch[2], S Kadiyala[1], B Bresnahan[1], L Garrison[1], *[1]University of Washington Phramaceutical Outcomes Research & Policy Program, United States, [2]University of Gelph, Canada*

P56 A phase 3 trial evaluating the safety, tolerability and immunogenicity of manufacturing scale 13-valent pneumococcal conjugate vaccine

J Gadzinowski[1], S Tansey[2], T Mellelieu[2], S Baker[3], PC Giardina[3], DA Scott[3], *[1]Univ. of Med. Sciences, Poland, [2]Wyeth Vaccines Research, United Kingdom, [3]Wyeth Vaccines Research, United States*

P57 Recombinant baculoviruses as vehicles for presentation and adjuvancy of antigens for the development of new TB candidate vaccines
P. Molinari[1], M.V. Bianco[1], A. Peralta[1], A.A. Cataldi[1], F. Bigi[1], O.A. Taboga[1], *[1]Institute of Biotecnology, INTA, Argentina*

P58 Age-specific serum IgA anti-Salmonella enterica serovar Typhimurium immune response in Yucatán, Mexico
I Secundino[1], M Fernández-Mora[1], F Martínez[2], JJ Calva[3], MB Zaidi[2], E Calva[1], *[1]UNAM, Mexico,[2]Hospital General O'Horan, Mexico,[3]INCMNSZ, Mexico*

P59 Liposome in In situ gelling system: Novel Carrier Based Vaccine Adjuvant for Intranasal Delivery of Recombinant Antigen Vaccine
Shailja tiwari[1], Amit Kumar Goyal[1], Neeraj Mishra[1], Bhuvaneshwar Vaidya[1], Suresh Prasad Vyas[1], *[1]1Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya, India*

P60 Invasive Pneumococcal Disease among Hospitalized Children in El Salvador. Seven years of Surveillance
Mario Antonio Gamero Rosalez[1], Dilcia Valencia[1], *[1]Hospital de Niños Benjamin Bloom, El Salvador*

P61 Identification of leptospirosis sub-unit vaccine candidates
S R Felix[1], E F da Silva[1], S D D Jouglard[1], D Hartmann[1], O A Dellagostin[1], *[1]Universidade Federal de Pelotas, Brazil*

P62 Cost-effectiveness analysis of HPV vaccination and screening in the prevention of cervical cancer in France: a multi-cohort Markov model
X. Lenne[1], D. Lévy-Bruhl[2], Y. Kudjawu[2], Y. Yazdanpanah[3], J.C. Desenclos[2], B. Dervaux[1], *[1]CRESGE/LEM, UMR CNRS 8179, Université Catholique de Lille, France,[2]Département des Maladies Infectieuses, InVS, France,[3]Service Universitaire des Maladies infectieuses et du voyageur, Centre hospitalier de Tourcoing, France*

P63 Immunisation of Children from 0 to 5 Years in Cameroon, Bonassama Health District After An Outbreak of Poliomyelities in 2008 in a Nearby Health District
S N MBUNYA[1], B A FOUDA[1], M E EDENGUE[1], *[1]MINISTRY OF PUBLIC HEALTH, BONASSAMA HEALTH DISTRICT, Cameroon*

P64 A mathematical model of the HPV-specific antibody production following immunization with a VLP-based vaccine
G. Olivera[1], A.C. Jacquard[2], B. Soubeyrand[2], F. Gueyffier[1], J.P. Boissel[1], *[1]The Institute for Theoretical Medicine, France,[2]Sanofi Pasteur MSD, France*

P65 Immunization of mice with Lactobacillus casei expressing intimin fragments induces antibodies able to inhibit the adhesion of enteropathogenic Escherichia coli to cultivated epithelial cells
PCD Ferreira[1], IB Campos[1], CM Abe[1], WP Elias[1], PL Ho[1], MLS Oliveira[1], *[1]Instituto Butantan, Brazil*

P66 A synthetic peptide encompassing the G5 antigenic region of the rabies virus induces high avidity but poorly neutralizing antibody in immunized animals
Simone Niederhäuser[1], Dorothy Brugger[1], Marie-Luise Zahno[1], Hans-Rudolf Vogt[1], Ernst Peterhans[1], Reto Zanoni[1], *[1]Institute of Veterinary Virology, Switzerland*

P67 Screening the Schistosoma mansoni transcriptome for genes differentially expressed in the schistosomula stage in search for vaccine candidates
LP Farias[1], CA Tararam[1], PA Miyasato[1], T Kawano[1], S Verjovski-Almeida[2], LCC Leite[1], *[1]Instituto Butantan, Brazil,[2]University of São Paulo, Brazil*

P68 Assessment of DNA Vaccination Strategies for Schistosomiasis Candidate Antigen, Sm-p80 in Mouse and Nonhuman Primate Models
G Ahmad[1], W Torben[1], R Damian[2], R Kennedy[1], R Wolf[3], A Siddiqui[1], *[1]Texas Tech University Health Sciences Center, United States,[2]University of Georgia, United States,[3]University of Oklahoma Health Sciences Center, United States*

P69 A Probiotic Dairy Product Improves Antibody Responses to Influenza Vaccination in the Elderly

S VAUDAINE[1], R BOURDET-SICARD[1], T BOGE[3], J TANGUY[1], S VAN DER WERF[2], SI SAMSON[1], *[1]Danone Research, France, [2]Pasteur Institute, France, [3]Geriatrician, France, [4]Geriatrician, France*

P70 A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda SF+ cells

N. Bonafé[1], J.A. Rininger[2], R.G. Chubet[2], S. Fader[1], H.G. Foellmer[3], J.F. Anderson[4], Raymond Koski[1], *[1]L2 Diagnostics, LLC, United States, [2]Protein Sciences Corporation, United States, [3]Yale University School of Medicine, United States, [4]Agricultural Experiment Station, United States, [5]University of Connecticut, United States*

P71 Newcastle Disease Virus-Like Particles as a Vaccine Platform

L W McGinnes[1], K Gravel[1], H Pantua[1], TG Morrison[1], *[1]University of Massachusetts Medical School, United States*

P72 Rotavirus vaccination uptake and compliance among managed care infants in the United States (US)

A.R. Sklar[1], J.E. Kemner[2], H.J. Henk[1], *[1]i3innovus, United States, [2]GlaxoSmithKline, United States*

P73 2005-2007 Mumps outbreak in the Czech Republic.

R Prymula[1], C Benes[2], M Kubinyiova[2], J Castkova[2], V Prikazsky[2], R Chlibek[1], *[1]Faculty of Military Health Sciences, University of Defence, Czech Republic, [2]National Institute of Public Health, Czech Republic*

P74 A vaccine candidate epitope anti- S. pyogenes associated with proteoliposome derived – cochleate adjuvant induces mucosal immune response in BALB/c mice.

L Guilherme[1], FT HIGA[1], E POSTOL[1], MT GUERINO[1], DS ROSA[1], SP RIBEIRO[1], *[1]Heart Institute,School of Medicine University of Sao Paulo, Brazil, [2]Clinical Immunology and Allergy, Department of Clinical Medicine; Medical School, University of São Paulo, Brazil, [3]Immunology Department, Finlay Institute, Cuba*

P75 Anti- S pyogenes vaccine candidate epitope was evaluated by using HLA class II DR and DQ transgenic mice.

J Kalil[1,2], E Postol[1], MT Guerino[1], FT Higa[1], LR Mundel[1], L Guilherme[1], *[1]Heart Institute (InCor) School of Medicine; University of Sao Paulo, Brazil, [2]Clinical Immunology and Allergy, Department of Clinical Medicine; Medical School, University of São Paulo, Brazil*

P76 Sanitary and socioeconimic impact of the virosomal subunit influenza vaccine in children without risk factors. Fuerteventura 2005-2006

A.J. Garcia Rojas[1], D Nuñez Gallo[1], M Naranjo Baez[1], *[1]Epidemiology Service, Spain, [2]Epidemiology Service, Spain, [3]Public Health Service, Spain*

P77 Simulation model for comparing the costs and effectiveness of different pneumococcal conjugate vaccines

P De Wals[1], *[1]Laval University, Canada*

P78 Tissue Vaccines for Prevention and Treatment of Prostate Cancer

M.A. Suckow[1], P. Hall[2], M.C. Hiles[2], *[1]University of Notre Dame, United States, [2]Cook Biotech, Inc., United States*

P79 Protection mediated by the Yersinia pestis F1-V plague vaccine in two animal models of plague: a contrast in immune response in murine and nonhuman primates.

K Amemiya[1], *[1]US Army Medical Research Institute of Infectious Diseases, United States*

P80 Induction of specific and protective T-cell immune responses to HBsAg by the use of 1/01/0023.

Anamika Khajuria[1], Pankaj Suden[1], Tabasum Sidiq[1], Sarang Bani[1], K.A Suri[1], N.K Satti[1], *[1]Indian Institute of Integrative Medicine, India*

P81 Screening Determines Monoclonal Specificity

K Jambunathan[1], H.M Geysen[1], *[1]University of Virginia, United States*

P82 Humoral and cellular immunity of dairy cattle one year after vaccination with a phase 1 Coxiella vaccine

A Rodolakis[1], P Clement[1,2], D Cochonneau[1], R Guatteo[2], P Sarradin[3], F Beaudeau[2], *[1]INRA UR 1282 IASP, France, [2]ENVN-INRA UMR1300 BIEPAR, France, [3]INRA UE 1277 PFIE, France*

P83 Effector Function and Efficacy of CD8+ T Cells Activated in the Absence of IFN-γ

M.H. Nelson[1], M.D. Bird[2], C-F Chu[1], G.N. Milligan[1], *[1]University of Texas Medical Branch, United States, [2]Loyola Medical Center, United States*

P84 Effector CD4+ T lymphocytes resolve acute Herpes Simplex Virus (HSV)-1 infection in neural tissues

AJ Johnson[1], C-F Chu[1], GN Milligan[1], *[1]University of Texas Medical Branch, United States*

P85 New Perspectives and Models for Hepatitis B vaccines and Immunization

Maria Rapicetta[1], *[1]Istituto Superiore di Sanita', Italy*

P86 Strong and Specific Protective and Therapeutic Immunity Induced by Single HLA-A2.1 Restricted Epitope DNA Vaccine in Rabbits

JH Hu[1], TS Schell[1], XP Peng[1], NMC Cladel[1], KKB Balogh[1], NDC Christensen[1], *[1]Pennsylvania State University, United States*

P87 Ferret Model of Avian Influenza Demonstrates Dose and Strain Dependant Pathology and Viral Load in Brain

RC Layton[1], P Armijo[1], L Myers[1], J Knight[1], *[1]Lovelace Respiratory Reseaerch Institute, United States, [2]Ibis Biosciences, Inc., United States*

P88 Intravital Microscopic Characterization of the Innate Immune Responses to Influenza

S.F. Gonzalez[1], M. Kuligowski[1], L.A. Pitcher[1], M.C. Carroll[1], *[1]IDI Institute, Harvard Medical School, United States*

P89 Mycobacterium Hsp65 DNA vaccine against murine model of Paracoccidiodomycosis

Alice Ribeiro[1], A Bocca[1], A Amaral[1], F Faccioli[2], F Figueiredo[1], CL Silva[1], MSS Felipe[1], *[1]University of Brasília, Brazil, [2]The Centre for Tuberculosis Research, University of São Paulo, Brazil, [3]Catholic University of Brasilia, Brazil, [4]Farmacore Biotecnologia, Brazil*

P90 Induction of immune response to Salmonella Typhimurium by the OmpS1 porin

I Secundino[1], E Calva[1], *[1]UNAM, Mexico*

P91 Oral therapeutic vaccination against dental caries in a rat model

Márcia D. Botelho Dinis[1,2], Delfina Tavares[1,2], Isabel Veiga-Malta[1,2], António J.M.M. Fonseca[3,4], Gabriela Trigo[1,2], Elva Bonifácio Andrade[1,2], *[1]ICBAS- Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Portugal, [2]IBMC- Instituto de Biologia Molecular e Celular, Universidade do Porto, Portugal, [3]Hospitais Universitários, Universidade de Coimbra, Portugal, [4]Faculdade de Medicina, Universidade Coimbra, Portugal*

P92 A Gag peptide encompassing B- and T- cell epitopes of the caprine arthritis encephalitis virus functions as modular carrier peptide

Simone Niederhäuser[1], Marie-Luise Zahno[1], Chiara Nenci[1], Hans-Rudolf Vogt[1], Reto Zanoni[1], Ernst Peterhans[1], *[1]Institute of Veterinary Virology, University of Bern, Switzerland*

P93 Entecavir treatment combined with DNA vaccine and recombinant fowlpox virus "prime-boost" vaccination for chronic hepatitis B virus infection

Feng Feng[1], Chee Quin Teoh[2], David Boyle[2], Allison Jilbert[1], *[1]School of Molecular & Biomedical Science, University of Adelaide, Australia, [2]CSIRO Livestock Industries, Australian Animal Health Laboratory, Australia*

P94 Immunomodulation by Nisin of Interferon Gamma and LPS Activity on Murine Macrophages

L. Oliveira-Nascimento[1], L.A.Jr Gerardi[2], D.G. Mafra[2], M.M. Borges[2], A.F Jozala[1], A. Pessoa Jr[1], *[1]School of Pharmaceutical Sciences - USP, Brazil, [2]Instituto Butantan, Brazil*

P95 Implication of Arginase and TGF-beta in NO Synthesis by Macrophage Activated by Bordetella Pertussis
A.S. Rosetti[1], J Abrahão Neto[2], C.S. Galhardo[1], M.A. Stephano[2], I.A. Abrahamsohn[3], M.M. Borges[1], *[1]Instituto Butantan, Brazil, [2]University of São Paulo, Brazil, [3]Instituto de Ciencias Biomédicas, Brazil*

P96 IL-12 Synthesis induced by Bordetella Pertussis and Parapertussis on Murine Macrophages
C.S. galhardo[1], A.S. Rosetti[1], P. Iamashita[1], L. Oliveira-Nascimento[2], M.A. Stephano[2], M.M. Borges[1], *[1]Instituto Butantan, Brazil, [2]School of Pharmaceutical Sciences, Brazil*

P97 Development of immunization strategies against leishmaniosis based on the Leishmania histones pathoantigens
J CARRION[1], C FOLGUEIRA[1], C ALONSO[1], *[1]CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA CSIC UAM, Spain*

P98 Evaluation of Enzyme-Linked Immunosorbent Assays-Based on MPL17 and MPL21 Recombinant Leptospiral Antigens for Serodiagnosis of Leptospirosis
AL Nascimento[1,2], TR Oliveira[1], MT Longhi[1], ZM Morais[3], *[1]Instituto Butantan, Brazil, [2]Interunidades Biotecnologia, Universidade de Sao Paulo, Brazil, [3]Universidade de Sao Paulo, Brazil, [4]Instituto Adolfo Lutz, Brazil, [5]SUCEN, Brazil*

P99 T-cell Vaccines that Elicit Effective Immune Responses against HCV in Chimpanzees Create Greater Immune Pressure for Viral Mutation
I Zubkova[1], Y Choi[2], E Chang[3], K Pirollo[3], H Krawczynski[2], M Major[1], *[1]CBER/Food and Drug Administration, United States, [2]Centers for Disease Control and Prevention, United States, [3]Georgetown University, United States*

P100 Shigella sonnei oligosaccharide-protein conjugates.
J Kubler-Kielb[1], E Vinogradov[2], C Mocca[1], R Schneerson[1], JB Robbins[1], *[1]NIH, United States, [2]NRC, Canada*

P101 Adjuvanted vaccine components: Analysis of structure and stability
M Kirkitadze[1], A Sinha[1], J Hu[1], W Williams[1], G Cates[1], *[1]Sanofi Pasteur Limited, Canada*

P102 Expression of Avian Influenza Virus Epitope (M2e) in fusion with Potato Virus X Coat Protein
A. Natilla[1], L.G. Nemchinov[1], *[1]Molecular Plant Pathology Laboratory,Plant Sciences Institute,United States Department of Agriculture, Agricultural Research Service, United States*

P103 Induction of anti-tumor immunity by the baculovirus Autographa californica multiple nuclear polyhedrosis virus
Hiroshi Takaku[1], Takashi Ave[1], Yoshiharu Matsuura[1], Masayuki Kitajima[1], *[1]Chiba Institute of Technology, Japan*

P104 In vivo Delivery of Herpes Simplex Type 1 Glycoprotein B Confers Substantial Protection against Genital Herpes
M Pistello[1], L Vannucci[1], F Chiuppesi[1], B Matteoli[1], R Manservigi[2], M Bendinelli[1], *[1]Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, Pisa, Italy, [2]Department of Experimental Medicine and Diagnostic, University of Ferrara, Ferrara, Italy*

P105 Molecular Epidemiology of Varicella-Zoster Virus Isolated from Herpes Zoster Patients in Vaccination Era
Kye-Hyung Kim[1], Young Ju Choi[1], Kyoung-Ho Song[1], Shinwon Lee[1], Hee-Chang Jang[1], Jae Hyun Jeon[1], *[1]Department of Internal Medicine, Seoul National University College of Medicine, Korea, Republic of*

P106 Correlating Early B Cell Responses With Long Term Protection: Towards A Fast Screening Assay For Vaccine Candidates
W. Wieland[1], J. Sijtsma[1], R. Boshuizen[2], W. van Eden[1], R.H. Meloen[2], R. van der Zee[1], *[1]Utrecht University, Netherlands, [2]Pepscan, Netherlands*

P107 Construction and characterization of mutant Dengue2 virus vaccine candidates displaying a host-range phenotype
K. M. Smith[1], K. Nanda[1], C. J. Slominski[1], R. Hernandez[2], D. T. Brown[2], M. E. Thomas[1], *[1]Arbovax, Inc., Raleigh, NC, United States, [2]North Carolina State University, Department of Molecular and Structural Biochemistry, Raleigh, NC, United States*

P108 The immune efficiency of a bivalent virus-like particle vaccine for human papillomavirus types 16 and 11
Hongxi Gu[1], Lanlan Wei[1], Ming Zhuan[1], Zhaohua ZHong[1], Fengmin Zhang[1], *[1]Department of Microbiology, China*

P109 Identification and Development of a Promising Novel Mumps Vaccine Candidate Strain
Yan Liang[1], Shaohui Ma[1], Longding Liu[1], Lichun Wang[1], Li Jiang[1], Qihan Li[1], *[1]Institute of medical biology, China*

P110 Immunogenic assay of one enterovirus 71 strain isolated during Epidemic in China and its adapting in fibroblast cell culture use as a vaccine candidate
Longding Liu[1], Shaohui Ma[1], Jiansheng Liu[1], Qihan li[1], *[1]Institute of medical biology, China*

P111 Rotavirus A genotypes circulating before and after the implementation of the monovalent vaccine in Rio de Janeiro, Brazil.
FA Carvalho Costa[1], IT Araujo[1], RMS Assis[1], AM Fialho[1], MN Bóia[3], JPG Leite[1], *[1]Laboratory of Comparative Virology, Oswaldo Cruz Institute, Brazil, [2]Salles Netto Municipal Hospital, Brazil, [3]Laboratory of Parasitic Diseases, Oswaldo Cruz Institute, Brazil*

P112 Safety and Tolerability of 3 lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the USA
T Payton[1], DA Scott[1,2], S Patterson[1,3], A Razmpour[1,2], D Girgenti[1,2], *[1]Northwest Arkansas Pediatrics, Fayetteville, AR,, United States, [2]Wyeth Vaccines Research, Pearl River, NY, United States, [3]Wyeth Research, Collegeville, PA, United States*

P113 Concentration and purification of influenza viruses by sulfate ester of cellulose (Cellufine Sulfate®)
Kouichi Ozaki[1], Yasuto Umeda[2], Shigeyuki Aoyama[2], Norikazu Isoda[1], Masatoshi Okamatsu[1], Yoshihiro Sakoda[1], *[1]Guraduate School of Veterinary Medicine, Hokkaido University, Japan, [2]Chisso Corporation, Japan*

P114 The Comparative Evaluation of Expanded National Immunization Policies in Korea Using an Analytic Hierarchy Process
T Shin[1], CB Kim[2], YH Ahn[2], HY Kim[2], BH Cha[2], Y Uh[2], *[1]College of Government & Business, Yonsei University, Korea, Republic of, [2]Yonsei University Wonju College of Medicine, Korea, Republic of*

P115 Reactogenicity of MenACWY-CRM administered sequentially or concomitantly with Tdap and HPV vaccines
A Arguedas[1], C Soley[1], C Loaiza[1], G Rincon[1], S Guevara[1], A Perez[1], *[1]Instituto de Atención Pediátrica San José, Costa Rica, [2]Novartis Vaccines and Diagnostics, Inc., Emeryville, CA, United States, [3]Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, United States*

P116 Bioinformatics prediction combined with synthesized peptides reveal an antigenic determinant of a membrane protein of LCDV-cn
S.Q. Wu[1], X.Q. Sun[1], J.X. Zhang[1], F.R. Zheng[1], *[1]First Institute of Oceanography, the State Oceanic Administration, China*

P117 Safety and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine Given Concomitantly with Trivalent Inactivated Influenza Vaccine in Healthy Adults
TF SCHWARZ[1], J FLAMAING[2], HC RUMKE[3], J J PENZES[4], C JUERGENS[5], A WENZ[5], *[1]Stiftung Juliusspital Wuerzburg, Germany, [2]Dept of Geriatric Medicine, Univ Hospital Leuven, Belgium, [3]Vaxinostics, Rotterdam, Netherlands, [4]Konszenzus Plusz Kft, Csongrád, Hungary, [5]Wyeth Research, Muenster, Germany, [6]Wyeth Vaccines Research, Pearl River, NY, United States, [7]Wyeth Research, Collegeville, PA, United States*

P118 Hepatitis B surface antigen-specific T cell memory in health care workers who have lost anti-HBs antibodies after hepatitis B vaccination over a period of time
Anuradha Tripathy[1], Mandeep Chadha[1], Rumki Das[1], Vidya Arankalle[1], *[1]National Institute of Virology, India*

P119 Mucosal immunisation against PBP2a reduces MRSA nasal colonisation in mice.
J.M.P. SENNA[1], S. GOUSSARD[1], C. GRILLOT-COURVALIN[1], *[1]Fiocruz (Fundaçao Oswaldo Cruz) - Bio-Manguinhos, Brazil, [2]Institut Pasteur, France, [3]Institut Pasteur, France*

P120 Vaccination among University Students: The Role of Parental Educational Attainment in Sustaining Vaccination Disparities
Gregory Cherkowski[1], Arnold Monto[1], Monica Uddin[1], Rebecca Coulborn[1], Allison Aiello[1], *[1]University of Michigan School of Public Health, United States*

P121 Withdrawn

P122 Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis
M Pavia[1], A Bianco[1], P Marinelli[2], IF Angelillo[2], P Crovari[2], *[1]1Chair of Hygiene, Medical School, University of Catanzaro "Magna Græcia", Italy, [2]2Department of Public, Clinical and Preventive Medicine, Second University of Naples, Italy*

P123 Impact of varicella vaccination coverage upon varicella-related hospitalizations in France and Germany: projections from a dynamic transmission model
T Van Effelterre[1], C Hogea[2], C Cohen[1], *[1]GlaxoSmithKline Biologicals, Rixensart, Belgium, [2]GlaxoSmithKline Biologicals, Philadelphia, United States*

P124 New Approaches for the Analysis of Bacterial Surface Exposed Proteins
N NORAIS[1], F BERLANDA SCORZA[1], M BIAGINI[1], F DORO[1], S LIBERATORI[1], I MARGARIT[1], *[1]Novartis Vaccines Diagnostics, Italy*

P125 Rapid Development and Validation of a T-Cell Epitope-Based Tularemia Vaccine for F. Tularensis
A DeGroot[1,2], L Moise[1,2], W Martin[1], R Tassone[1], J Desrosiers[1], J McMurry[1], *[1]EpiVax, Inc., Providence RI, United States, [2]University of Rhode Island, United States, [3]Brown University, Providence, RI, United States*

P126 A "Venn" Vaccine: Selection and Validation of Vaccinia-Variola-Conserved Epitopes
L Moise[1,2], A De Groot[1,2], J McMurry[2], J Desrosiers[2], R Tassone[2], W Martin[2], *[1]Institute for Immunology and Informatics, University of Rhode Island, Providence, RI, United States, [2]EpiVax, Providence, RI, United States, [3]U. Mass Medical School, Worcester, MA, United States, [4]Saint Louis University, Saint Louis, MO, United States*

P127 The Gaia HIV Vaccine Progress Report: Broad Recognition of Class I and II Restricted Epitopes and In Vivo Studies
A De Groot[1,2], L Moise[1,3], J Desrosiers[1], R Tassone[1], W Martin[1], K Coulibaly[2], *[1]EpiVax, Providence, RI, United States, [2]Faculté de Sciences et Technologie, Bamako, Mali, Mali, [3]Institute for Immunology and Informatics, Providence, RI, United States*

P128 Role of Tregs: Insights for the design of improved Hepatitis C vaccine
A De Groot[2], L Shuo[1], S Floess[3], G Silvana[4], A Lucas[3], A Hamann[2], *[1]Macfarlane Burnet Institute for Medical Research and Public Health, Melbourne, Victoria, Australia, Australia, [2]EpiVax, Inc. Providence RI USA, United States, [3]Experimental Rheumatology, Charite´ University Medicine Berlin, Germany, Germany, [4]4Centre for Clinical Immunology and Biomedical Statistics, Perth, Western Australia, Australia*

P129 Effect of Maternal Antibodies on Infant Pertussis Vaccination
Monika Polewicz[1], Anastasia Nijnik[2], Robert E.W. Hancock[2], Lorne Babiuk[1], Scott Halperin[3], Volker Gerdts[1], *[1]VIDO, University of Saskatchewan, Canada, [2]Centre for Microbial Diseases and Immunity Research, Canada, [3]Canadian Center for Vaccinology, Canada*

P130 Recombinant Alphavirus Replicons as a Potential Screening Approach to Evaluate Immunogenicity of Newly Designed HIV Vaccine Envelopes

Michael Franti[1], Indresh Srivastava[1], Susan Barnett[1], *[1]Novartis Vaccines and Diagnostic, Inc, United States, [2]Regional Primate Center, UC Davis,, United States*

P131 Bicistronic Plasmid Approach for DNA Vaccine Development Against African Trypanosomiasis

MS Silva[1], E Martinez-Salas[2], AS Lança[1], KP De Sousa[1], C Ferrão[1], GA Monteiro[3], *[1]Center for Malaria and Tropical Diseases - Institute of Hygiene and Tropical Medicine. Lisbon, Portugal, [2]Centro de Biologia Molecular Severo Ochoa - Universidad Autonoma de Madrid. Madrid, Spain, [3]Institute for Biotechnology and Bioengineering - Instituto Superior Técnico. Lisbon, Portugal*

P132 Structure based rational design of HIV Env immunogens for vaccine development

IK Srivastva[1], K Hartog[1], Zohar Biron[1], E Kan[1], Yi DE Sun[1], Y Lian[1], *[1]Novartis Vaccines and Diagnostics, Inc.,Cambridge, MA, United States, [2]Novartis Vaccines and Dianostics, Inc., Siena, Italy*

P133 EpiMatrix: Tool for Accelerated Epitope Selection and Vaccine Design

M Ardito[1], A De Groot[1], J McMurry[1], L Moise[1], W Yang[1], B Martin[1], *[1]1EpiVax, Inc. Providence RI, United States, [2]2Institute for Immunology and Informatics, University of Rhode Island, United States*

P134 Immunoprophylactic Activity of a CpG-Containing Immunogen on the Development of Experimental Respiratory Allergy to Blomia Tropicalis

David Andrade[1], Tassia Lopes[1], Virginia Silva[1], Neuza Neves[2], Lain Carvalho[1], *[1]Centro de Pesquisa Gonçalo Moniz - FIOCRUZ, Brazil, [2]Universidade Federal da Bahia, Brazil*

P135 Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-g and cytolytic activity by CD8+ T cells

Ana Paula Fernandes[1], Daniela Resende[1], Bráulia Caetano[1], Míriam Dutra[1], Marcus Penido[1], Christiane de Abrantes[5], *[1]Federal University of Minas Gerais, Brazil, [2]Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts,, United States, [3]University of Ouro Preto – Ouro Preto, MG, Brazil, Brazil, [4]Rene Rachou Institute, Oswaldo Cruz Foundation – Belo Horizonte, MG, Brazil, Brazil, [5]Hertape Calier Saude Animal, Brazil*

P136 Protective immunity against challenge with Leishmania chagasi in susceptible beagle dogs vaccinated with recombinant A2 protein

Ana Paula Fernandes[1], Miriam Silva Costa[1], Eduardo Ferraz Coelho[1], Marilene Michalick[1], Eloisa de Freitas[1], Wagner Tafuri[1], *[1]Federal University of Minas Gerais – Belo Horizonte, MG, Brazil, Brazil, [2]Rene Rachou Institute, Oswaldo Cruz Foundation – Belo Horizonte, MG, Brazil;, Brazil, [3]Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA, United States, [4]Laboratório Hertape Calier Saúde Animal – Juatuba, MG, Brazil, Brazil*

P137 Immunity against porcine circovirus 2 by vaccination with ORF2-based DNA in mice

Ji-Yong Zhou[1,2], Hui-Gang Shen[1,2], Zhen-Yu Huang[1,2], Jun-Qing Guo[1,2], Gang Xing[1,2], Jia-Ling He[1,2], *[1]Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, Institute of Preventive Veterinary Medicine, Zhejiang University, China, [2]State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University, Hangzhou 310029, China*

P138 Recombinant alphavirus and adjuvanted protein vaccines delivered mucosally and systemically protect macaques from mucosal SHIV challenges

SW Barnett[1], M Vajdy[1], B Burke[1], J zur Megede[1], E Kan[1], Y Lian[1], *[1]Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, United States, [2]Novartis Vaccines and Diagnostics, Inc., Siena, Italy*

P139 In vitro expression and bioactivity of duck interleukin-2
Ji-Yong Zhou[1], Jin-Yong Wang[1], Ji-Gang Chen[1], *[1]Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, Institute of Preventive Veterinary Medicine, Zhejiang University, Hangzhou 310029, China*

P140 Production and characterization of monoclonal antibody to duck CD8α
ZY Huang[1,2], JY Gu[1,2], QY Teng[1,2], HB Li[1,2], JQ Guo[1,2], JY Zhou[1,2], *[1]Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, China, [2]State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, China*

P141 The molecular mechanism of attenuation for IBDV NB strain passaged on CEF
Lixue Shi[1,2], Haibin Li[1,2], Guangpeng Ma[1,3], Jiyong Zhou[1,2], Lianlian Hong[1,2], Xiaojuan Zheng[1,2], *[1]Key Laboratory of Animal Epidemic Etiology & Immune control of Ministry of Agriculture, China, [2]State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, China, [3]China Rural Technology Development Center, China*

P142 Transcription analysis and prokaryotic expression of chicken IL-2 receptor gamma chain gene
Gu Jianyou[1], Teng Qiaoyang[1], Wang Zhenyu[1], Zhou Jiyong[1], *[1]Institute of Preventive Veterinary Medicine, China*

P143 In vitro anti-viral activity of serum from mice immunized with liposomes containing the M2 ectodomain (M2e) of the influenza virus
W. Ernst[1], M. Munoz[2], H. Kim[2], G. Fujii[1], J. Adler-Moore[2], B Mothé[2], *[1]Molecular Express, Inc., United States, [2]California State Polytechnic University, Pomona, United States*

P144 Immunological Characterization of Liposomal HSV2 gD fusion protein in BALB/c Mice
J. Adler-Moore[1], K. Olson[1], P. Macias[1], W. Ernst[2], G. Fujii[2], *[1]California State Polytechnic University, Pomona, United States, [2]Molecular Express, Inc., United States*

P145 Factors associated with Pneumococcal immunization among hospitalised elderly persons: A survey of patient's perception, attitude, and knowledge
I Ridda[1,2], RI Lindley[2,3], PB McIntyre[1,4], CR MacIntyre[1,5], *[1]National Centre for Immunisation Research and Surveillance., Australia, [2]The University of Sydney, Australia, [3]Discipline of Medicine: Geriatric Medicine. The University of Sydney, Australia, [4]Discipline of Paediatrics and Child Health. The University of Sydney, Australia, [5]School of Public Health and Community Medicine. The University of New South Wales, Australia*

P146 Differences in attitudes, beliefs and knowledge of hospital health care workers and community doctors to vaccination of older people
I Ridda[1,2], R Lindley[2,3], Z Gao[1,4], P McIntyre[1,2], CR MacIntyre[1,4], *[1]National Centre for Immunisation Research and Surveillance., Australia, [2]The University of Sydney, Australia, [3]Discipline of Medicine: Geriatric Medicine. The University of Sydney, Australia, [4]School of Public Health and Community Medicine. The University of New South Wales, Australia*

P147 The benefit of molecular characterization during a measles upsurge in Denmark
M. Muscat[1], L. Vinner[2], A.H. Christiansen[1], S. Glismann[1], B.E. Böttiger[2], *[1]Department of Epidemiology, Statens Serum Institut, Denmark, [2]Department of Virology, Statens Serum Institut, Denmark*

P148 Measles hotspots in Europe
M Muscat[1], H Bang[1], J Wohlfahrt[2], S Glismann[1], K Mølbak[1], EUVAC.NET group[3], *[1]Department of Epidemiology, Statens Serum Institut, Denmark, [2]Department of Epidemiology Research, Statens Serum Institut, Denmark, [3]European public health and surveillance institutions, ...*

P149 Selecting Staphylococcus aureus vaccine candidates
Fabio Bagnoli[1], Luigi Fiaschi[1], Masimiliano Biagini[1], Nathalie Norais[1], Maria Scarselli[1], Francesco Doro[1], Ilaria Ferlenghi[1], Claudio Donati[1], Rino Rappuoli[1], Guido Grandi[1], *[1]Novartis Vaccines and Diagnostics, Italy*

P150 Nasal Delivery of an Ebola Adenovirus-Based Vaccine Bypasses Pre-existing Immunity to the Vaccine Carrier
Maria Croyle[1], Mickey Sahib[1,2], Ami Patel[2,3], Kaylie Tran[2], Michael Gray[2], Yi Zhang[4], James Strong[4], Heinz Feldmann[4], Gary Kobinger[4], *[1]The University of Texas at Austin, United States, [2]Public Health Agency of Canada, Canada, [3]University of Manitoba, Canada, [4]University of Michigan, United States*

P151 Global HIV Vaccine Research Cryorepository - GHRC
H. von Briesen[1], E. M. Fenyö[2], H. Holmes[3], E. V. Karamov[4], A. Meyerhans[5], M. Morgado[6], *[1]Fraunhofer IBMT, Germany, [2]University of Lund, Sweden, [3]NIBSC, United Kingdom, [4]Ivanovski Instituthttps://elsevier.conference-services.net/resources/spacer.gife, Russian Federation, [5]University of Saarland, Germany, [6]FIOCRUZ, Brazil, [7]WHO, Switzerland, [8]Stellenbosch University, South Africa, [9]Fondazione San Raffaele, Italy, [10]NIH, United States, [11]Siriraj Hospital, Thailand*

P152 Development of the auxotropic selection marker and production technology for the DNA plasmid based genetic vaccine vectors.
M. Ustav[1,3], T. Tenson[3], K. Reijonen[2], U. Toots[1], T. Kärkkäinen[2], A. Männik[1], *[1]FIT Biotech Oy Eesti AS, Estonia, [2]FIT Biotech Oy, Finland, [3]Institute of Technology, University of Tartu, Estonia*

P153 A Network for Supporting Vaccine Development in Europe
TJG Brooks[1], JM Duggan[1], BAM van der Zeijst[2], J Hendriks[2], *[1]Health Protection Agency, United Kingdom, [2]Netherlands Vaccine Institute, Netherlands*

P154 Towards a Global Vaccine Safety Datalink: Rationale, Available Infrastructure Globally and Progress to Date.
S.B. Black[1], *[1]Center for Global Child Health, Cincinnati Childrens' Hospital, United States*

P155 Cationic bilayer fragments as immunoadjuvants
N. Lincopan[1], N.M. Espíndola[1], A.J. Vaz[1], A.M. Carmona-Ribeiro[1], *[1]Universidade de São Paulo, Brazil*

P156 Silica-based cationic bilayers as immunoadjuvants
N. Lincopan[1], M.R.A. Santana[1], M.H.B. Costa[2], E.L. Faquim-Mauro[2], A.M. Carmona-Ribeiro[1], *[1]Universidade de São Paulo, Brazil, [2]Instituto Butantan, Brazil*

P157 Genetic interaction of vaccinia virus with cells and its oncological safety
A.D. Altstein[1], N.F. Grinenko[1], L.G. Zakharova[1], L.M. Piskareva[1], G.V. Pashvykina[1], *[1]Institute of Gene Biology, Russian Federation*

P158 Induction of Immune Response of Hepatitis B Vaccine Using Polyester Polymer as an Adjuvant
S M SIVAKUMAR[1], N SUKUMARAN[1,2], *[1]Division of Research and Development, Nehru College of Pharmacy, India, [2]Sri Paramakalyani Centre for Environmental Sciences, India*

P159 An Immunoregulatory Role for Cyclooxygenase-2 in Human B Lymphocytes Stimulated with CpG Oligodeoxynucleotides: Implications for Vaccination
M.P. Bernard[1], R.P. Phipps[1], *[1]University of Rochester School of Medicine and Dentistry, United States*

P160 Biodegradable Polymeric Nanoparticles as Vaccine Delivery Systems
S.A. Ferreira[1], F.M. Gama[1], *[1]IBB-Institute for Biotechnology and Bioengineering, Centre for Biological, Portugal*

P161 Effect of combination adjuvants composed of aluminium salts and TLR4 agonists on the immune response
A. Sokolovska[1], H. HogenEsch[1], *[1]Purdue University, United States*

P162 Effect of the dose of aluminum adjuvants on the immune response
K.M. Anderson[1], H. HogenEsch[1], *[1]Purdue University, United States*

P163 Effective induction of anti-tumor immune responses with oligomannose-coated liposomes targeting to intraperitoneal macrophages
K Tsujimura[1], Y Ikehara[2], T Nagata[1], Y Koide[1], N Kojima[3], *[1]Hamamatsu University School of Medicine, Japan, [2]National Institute of Advanced Industrial Science and Technology, Japan, [3]Tokai University, Japan*

P164 The Use of Soluble Trimers of African Horsesickness - or Bluetongue Virus VP7 as a Display Vector for Presenting Immunologically Important Peptides to the Immune System
QC Meyer[1], D Rutkowska[1], W Fick[1], W Vosloo[2], H Huismans[1], *[1]University of Pretoria, South Africa, [2]Onderstepoort Veterinary Institute, South Africa*

P165 Use Of Alphavirus Replicons Expressing IL-12 As Highly Potent Vaccine Adjuvants
P Berglund[1], B Hubby[2], WC Lewis[1], LO Copp[2], SH Timberlake[1], EK Wansley[1], *[1]AlphaVax, Inc., United States, [2]Liquidia Technologies, Inc., United States*

P166 Nanoparticle Based Combinatorial TLR Ligand Delivery Mediates Synergistic Immune Responses
Sudhir Pai Kasturi[1], Marcin Kwissa[1], Michael Heffernan[2], Niren Murthy[2], Bali Pulendran[1], *[1]Emory University, United States, [2]Georgia Institute of Technology, United States*

P167 4-1BB Costimulation as an Adjuvant for HIV-1 DNA Vaccine: Different Effects by Anti-4-1BB Agonist Ab and 4-1BBL DNA
S Ganguly[1], J Liu[1], R Mittler[1], R Amara[1], *[1]Emory University, United States*

P168 Japanese Encephalitis Virus DNA Vaccine Using The Transcutaneous Immunization By Chitosan Complexes
Chang-Jer Wu[1], Hang-Ning Huang[1], *[1]Department of Food Science, National Taiwan Ocean University, Taiwan*

P169 Alphavirus Null Replicon Particles as a Novel Adjuvant Technology. Early Studies in Rodents and Non-human Primates.
Mario Barro[1], Daniel Tonkin[1], Nancy Davis[2], Ande West[2], Linda Fritts[3], Chris Miller[3], Clayton Beard[1], Robert Johnston[1,2], *[1]Global Vaccines Inc, United States, [2]Carolina Vaccine Institute at UNC, United States, [3]California National Primate Research Center at UC Davis, United Kingdom*

P170 Bacillus subtilis as Particulate Adjuvant for Rabies Animal Vaccine
MA Stephano[2], *[1]Butantan Institute, Brazil, [2]Sao Paulo University, Brazil*

P171 Sequential delivery of different cytokine genes as a novel adjuvant "prime-boost" strategy to enhance immune responses and CD4+ T memory cells
B Wang[1], B Su[1], Y Kang[1], *[1]China Agricultural University, China*

P172 Potent Adjuvant Formula Conferred by Triple Synergism Consisting of CpG, CL097, and MDP
J Lee[1], A Dhamko[1], H Kornfeld[1], *[1]Umass Med, United States*

P173 Vaxfectin®, a Cationic Lipid-based Adjuvant for Protein-based Influenza Vaccines
J. Hartikka[1], V. Bozoukova[1], C. K. Yang[1], D. Rusalov[1], M. Shlapobersky[1], Q. Wei[1], *[1]Vical Incorporated, United States*

P174 Analysis of Biomarkers after Intramuscular Injection of Vaxfectin®-formulated Antigens in Mice
M Shlapobersky[1], Q Wei[1], J Hartikka[1], S Sullivan[1], A Vilalta[1], *[1]Vical Inc., United States*

P175 Decrease of CD4/CD25 T cell and increase of IFN-gamma in dog vaccinated with Leishmune an endemic area for visceral leishmaniasis
Valéria Lima[1], Fabiana Ikeda[1], Mary Feitosa[1], Rosimere Vasconcelos[3], Cáris Nunes[2], Hiro Goto[4], *[1]Universidade Estadual Paulista- Faculdade de Odontologia- Departamento de Clínica, Cirurgia e Reprodução Animal, Brazil, [2]Universidade Estadual Paulista- Faculdade de Odontologia- Departamento de Apoio Produção e Saúde, Brazil, [3]Universidade Estadual Paulista- Faculdade de Ciências Agrárias e Veterinárias- Departamento de Patologia, Brazil, [4]Universidade de São Paulo - Faculdade de Medicina - Departamento de Medicina Preventiva, Brazil*

P176 Characterization of Tly proteins of Leptospira revealed that TlyC is an ECM binding protein but it is not a protective antigen against leptospirosis.
E. Carvalho[1,2], A.S. Barbosa[1], R.M. Goméz[3], E.C. Romero[4], S.A. Vasconcellos[5], P.L. Ho[1], *[1]Instituto Butantan, Brazil, [2]Instituto de Biociências da USP, Brazil, [3]CONICET-UNLP, Argentina, [4]Instituto Adolpho Lutz, Brazil, [5]Faculdade de Medicina Veterinária e Zootecnia da USP, Brazil*

P177 Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis (CVL)
GP Borja-Cabrera[1], FB Santos[1], E Picillo[2], AE Gravino[2], L Manna[2], CB Palatnik-de-Sousa[1], *[1]Federal University of Rio de Janeiro, Brazil, [2]Universita di napoli Federico II, Italy*

P178 The Nucleoside hydrolase DNA vaccine VR1012NH36 in prophylactic vaccination against mice tegumentar leishmaniaisis
LOP Souza[1], CB Palatnik-de-Sousa[1], *[1]Federal University of Rio de Janeiro, Brazil*

P179 The FML-vaccine against canine visceral leishmaniasis: from the second generation to the synthetic vaccine.
CB Palatnik-de-Sousa[1], *[1]Federal University of Rio de Janeiro, Brazil*

P180 Cloning of the Nucleoside hydrolase of Leishmania donovani aiming the development of a synthetic vaccine against visceral leishmaniasis
D Nico[1], C Claser[2], I Soares[3], MM Rodrigues[2], CB Palatnik-de-Sousa[1], *[1]Federal University of Rio de Janeiro, Brazil, [2]UNIFESP-Cintergen, Brazil, [3]USP, Brazil*

P181 A New Subunit Vaccine Based on Nucleocapsid Protein Nanoparticles Confers Partial Protection in Calves Against Respiratory Syncytial Virus
S Riffault[1], G Durand[1], M Soulestin[2], C Dubuquoy[1], M Deplanche[2], N Castagné[1], *[1]UR892 INRA, France, [2]UMR 1225 INRA-ENVT, France, [3]UE1277 INRA, France, [4]SEPPIC, Air Liquide, France*

P182 How to implement vaccination against Coxiella burnetii infection in infected dairy herds?
F. Beaudeau[1], R. Guatteo[1], A. Rodolakis[2], H. Seegers[1], *[1]Ecole Vétérinaire-INRA, UMR 1300 BioEpAR, France, [2]INRA, UR 1282 IASP, France*

P183 Priming of a mucosal response following parenteral DNA vaccination in pigs?
V Melkebeek[1], E Cox[1], BM Goddeeris[1], *[1]Ghent University, Laboratory of Veterinary Immunology, Belgium*

P184 Safety and immune responses in Guinea pigs and Pigs immunized with an inactivated vaccine containing three subtypes of swine influenza virus (H1N1, H1N2, H3N2) and Mycoplama hyopneumonia
DS Song[1], CS Lee[1], BK Park[2], BK Kang[1], *[1]Green Cross Veterinary Products, Korea, Republic of, [2]Department of Veterinary Medicine Virology Lab, College of Veterinary Medicine, Seoul National University, Korea, Republic of*

P185 Efficacy of Live attenuated and Inactivated Oil Emulsion Infectious Bursal Disease Virus Vaccines in Broiler
NAZIR AHMAD[1], SHAFQAT FATIMA[1], SHAHANA KAZMI[1], *[1]UNIVERSITY OF KARACHI AND SINDH POULTRY VACCINE CENTRE, Pakistan*

P186 An acellular vaccine delivered in microparticles confers protection against Brucella ovis infection in rams
C Gamazo[1], R Martins[2], JM Blasco[3], MP Muñoz[3], CM Marín[3], MJ Grilló[3], *[1]Dpt. Microbiology. University of Navarra, Spain, [2]Dpt. Pharmacy. University of Navarra, Spain, [3]SIA-DGA, Spain*

P187 Adjuvant formulation for veterinary vaccines: Montanide™ Gel safety profile.
SD Deville[1], AL Laval[2], RP Parker[3], FB Bertrand[1], LD Dupuis[1], JA Aucouturier[1], *[1]SEPPIC, France, [2]ENVN, France, [3]SEPPIC Inc, United States*

P188 Identification of Marek's Disease Virus Genes Mutated During Serial Passage-Induced Attenuation
SJ Spatz[1], IM Gimeno[2], M Heidari[3], *[1]USDA ARS Southeast Poultry Research Laboratory, United States, [2]North Carolina State University, United States, [3]USDA ARS Avian Disease and Oncology Laboratory, Germany*

P189 An IPNV oral vaccine using VP2 sub-viral particles (sVLP) and display of human oncogene c-myc marker on sVLP.
Arun Dhar[1], Robert Bowers[1], Christopher Rowe[1], Vikram Vakharia[2], Scott LaPatra[3], Franklin Allnutt[1], *[1]Advanced BioNutrition Corp., United States, [2]University of Maryland, United States, [3]Clear Springs Food, Inc., United States*

P190 Oral vaccination of Atlantic Salmon Salmo salar against Salmonid rickettsial septicaemia (SRS).
Jamie Tobar[1], Tommy Jakovljevic[1], Paula Aedo[1], Moti Harel[2], Arun Dhar[2], Thomas Goodrich[1], *[1]Laboratorios Centrovet, Chile, [2]Advanced BioNutrition Corp, United States*

P191 Design of a multi-epitope vaccine against Staphylococcus aureus
M JOLOIS[1], B TAMINIAU[1], N RHAZI[1], A JACQUET[2], E HEINEN[1], *[1]University of Liège, Belgium, [2]Free University of Brussels, Belgium*

P192 Restriction Fragment Length Polymorphism of Pakistani Field Isolates of Infectious Bursal Disease Virus (IBDV)
NAZIR AHMAD[1], SHAFQAT REHMANI[1], SHAHANA KAZMI[1], *[1]DEPARTMENT OF MICROBIOLOGY, UNIVERSITY OF KARACHI,, Pakistan*